New manufacturing processes could produce bird flu vax ASAP

FierceBiotech reports today that Novartis ($NVS) and Novavax ($NVAX) have had good results from early trials of new bird flu vaccines that could be used to protect against the deadly H7N9 strain. As important as the effectiveness of the vaccines is the fact that by using new manufacturing processes, the vaccines could be available in quantity ASAP. The Biomedical Advanced Research and Development Authority (BARDA) is underwriting some of the research and construction of manufacturing allowing the rapid production. According to Reuters, BARDA Director Robin Robinson said today that computer models found that by using the Novavax vaccine and manufacturing process, for example, manufacturers could produce the first doses of H7N9 vaccine within 12 weeks of the emergence of a pandemic, 50 million doses within four months, and hundreds of millions of doses within 6 months. Story | More